These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28944534)

  • 21. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 22. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

  • 24. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
    Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
    JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
    [No Abstract]   [Full Text] [Related]  

  • 25. Ipilimumab/nivolumab-induced pseudolymphoma in a patient with malignant melanoma.
    Ayoubi N; Haque A; Vera N; Ma S; Messina J; Khushalani N; Seminario-Vidal L
    J Cutan Pathol; 2020 Apr; 47(4):390-393. PubMed ID: 31677178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
    Grimaux X; Delva R; Jadaud E; Croue A
    Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 28. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
    Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
    Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
    Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
    Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment.
    Fukuchi K; Shimauchi T; Fujiyama T; Ito T; Honda T
    Eur J Dermatol; 2023 Oct; 33(5):550-551. PubMed ID: 38297931
    [No Abstract]   [Full Text] [Related]  

  • 34. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
    J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange.
    Waki Y; Nobeyama Y; Chujo S; Asahina A
    J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735
    [No Abstract]   [Full Text] [Related]  

  • 36. Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event.
    Mangas C; Leoni-Parvex S; Spataro V
    Cancer Immunol Immunother; 2020 Nov; 69(11):2409-2410. PubMed ID: 32964272
    [No Abstract]   [Full Text] [Related]  

  • 37. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
    Latchman J; Guastella A; Tofthagen C
    Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab plus ipilimumab in metastatic colorectal cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
    [No Abstract]   [Full Text] [Related]  

  • 39. Dual checkpoint inhibitor-associated eosinophilic enteritis.
    Yang J; Lagana SM; Saenger YM; Carvajal RD
    J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.